| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss (gain) on long-term investments, net | NaN | -197 | NaN | NaN |
| Change in fair value of preferred stock warrants | NaN | 0 | 0 | 0 |
| Net loss | -41,488 | -35,896 | -16,700 | -29,531 |
| Depreciation and amortization | 111 | 107 | 125 | 55 |
| Loss on disposal of property and equipment | NaN | 0 | NaN | NaN |
| Loss on impairment of operating right-of-use assets and related property and equipment | 0 | 0 | 0 | 82 |
| Accretion of discounts and amortization of premiums on marketable securities, net | 316 | 608 | 779 | 2,022 |
| Write-off of nonsalable inventory | 414 | NaN | NaN | NaN |
| Share-based compensation expense | 4,319 | 3,678 | 3,469 | 5,400 |
| Accounts receivable, net | 14 | 329 | NaN | NaN |
| Inventory | 889 | 3,326 | 949 | NaN |
| Prepaid expenses and other current assets | 341 | 1,924 | -93 | 1,196 |
| Accounts payable | 6,762 | -156 | 1,694 | -1,628 |
| Accrued liabilities | -2,114 | 5,029 | 4,459 | 1,487 |
| Operating lease liabilities, net | -27 | NaN | NaN | NaN |
| Other assets | -1 | -203 | 0 | 204 |
| Net cash used in operating activities | -33,582 | -33,025 | -8,588 | -27,557 |
| Purchases of marketable securities | 16,056 | 133,112 | 56,306 | 91,385 |
| Proceeds from maturities of marketable securities | 49,235 | 43,340 | 52,412 | 110,210 |
| Purchases of property and equipment | 18 | 38 | 439 | 350 |
| Net cash provided by investing activities | 33,161 | -89,810 | -4,333 | 18,475 |
| Proceeds from issuance of common stock under employee stock purchase plan | NaN | 648 | 0 | 225 |
| Cash, cash equivalents, and restricted cash acquired in connection with the merger | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock, net of issuance costs-Private Placement | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock, net of issuance costs-At The Market Offerings | NaN | 121,682 | 0 | 26,067 |
| Merger transaction costs | NaN | 0 | 0 | 0 |
| Proceeds from exercises of stock options | 14 | 285 | 598 | 240 |
| Net cash provided by financing activities | 14 | 122,615 | 598 | 26,532 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -407 | -220 | -12,323 | 17,450 |
| Cash, cash equivalents, and restricted cash, beginning of the period | NaN | 25,399 | 20,272 | NaN |
| Cash and cash equivalents and restricted cash, beginning of the period | 25,179 | NaN | NaN | NaN |
| Cash, cash equivalents, and restricted cash, end of the period | NaN | 25,179 | 25,399 | NaN |
| Cash, cash equivalents and restricted cash, end of the period | 24,772 | NaN | NaN | NaN |
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. (LENZ)